日本語 
Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling’s cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park.
The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually.
That matters as Kyowa Kirin’s research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform’s analytical and AI capabilities.
Also Read: Agentic AI in Healthcare: Why Microsoft’s New Approach Could Reshape the Industry
Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too.
This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool.
English